Satellos Bioscience Inc (MSCLF)

[ListenToMe]

Fri, 27 Feb '15 | 1:15 AM ET
PR Newswire
DALLAS, February 27, 2015 /PRNewswire/ --
RnRMarketResearch.com adds Corneal Ulcers - Pipeline Review, H2 2014 market research report to its store. This report p provides an overview of the Corneal Ulcers' therapeutic pipeline.
The report "Corneal Ulcers - Pipeline Review, H2 2014" provides comprehensive information on the therapeutic development for Corneal Ulcers. Corneal Ulcers are primarily result of the various infections that includes bacterial infections, viral infections & fungal infections. The symptoms of the corneal Ulcers include red eye, pain in the eyes, continuous draining of the eyes, difficulty in vision when exposed to bright light and others. An ophthalmologist makes a diagnosis of the corneal ulcer by putting the area under magnified view of slit lamp. Complete research is available at http://www.rnrmarketresearch.com/corneal-ulcers-pipeline-review-h2-2014-market-report.html .
The report has complete comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dementia and special features on late-stage and discontinued projects features on late-stage and discontinued projects. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Order a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=256205 . (This is a premium report priced at US$2000 for a single user License.)
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. Companies discussed in this Corneal Ulcers - Pipeline Review, H2 2014 report include Digna Biotech, S.L., Lee's Pharmaceutical Holdings Limited. This report also provides drugs profile includes in this report are disitertide, Drug for Parasitic Corneal Ulcers, NL-005, P-17, ZK-003.
Scope of Corneal Ulcers - Pipeline Review, H2 2014 covers: a snapshot of the global therapeutic landscape of Corneal Ulcers; report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities; reviews key players involved in the therapeutics development for Corneal Ulcers and enlists all their major and minor projects; summarizes all the dormant and discontinued pipeline projects; A review of the Corneal Ulcers products under development by companies and universities/research institutes based on information derived from company and industry-specific sources; Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages; A detailed assessment of monotherapy and combination therapy pipeline projects; Coverage of the Corneal Ulcers pipeline on the basis of target, MoA, route of administration and molecule type as well as Latest news and deals relating related to pipeline products.
Reasons to buy
Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop strategic initiatives by understanding the focus areas of leading companies
Identify and understand important and diverse types of therapeutics under development for Corneal Ulcers
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Devise corrective measures for pipeline projects by understanding Corneal Ulcers pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Explore more reports on Ophthalmology therapeutics @ http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/ophthalmology-therapeutics .
Keratitis - Pipeline Review, H2 2014
This report provides comprehensive information on the therapeutic development for Keratitis. Companies discuss in the report include Adamis Pharmaceuticals Corporation, Cellceutix Corporation, Dompe Farmaceutici S.p.A., Kala Pharmaceuticals, Inc., Peregrine Pharmaceuticals, Inc., RegeneRx Biopharmaceuticals, Inc., Sirnaomics, Inc. Drug Profiles discussed in this report include brilacidin, C-31G, IBN-1, loteprednol etabonate, moxifloxacin hydrochloride, PGN-632, PIM-45, Recombinant Human Nerve Growth Factor, RGN-259, Small Molecules to Inhibit ATM for Herpes Keratitis, STP-601, targocil, tigecycline.
Anterior Uveitis - Pipeline Review, H2 2014
This report provides comprehensive information on the therapeutic development for Anterior Uveitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Companies discuss in the report include EyeGate Pharmaceuticals, Inc., Neuroptis Biotech, Virogenomics, Inc., XOMA Corporation.
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2015
This report provides comprehensive information on the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration. Companies discuss in the report include Alcon, Inc., Allergan, Inc., AlphaMab Co., Ltd, Amakem NV, Avalanche Biotechnologies, Inc., Bayer AG, BIOCAD, Boehringer Ingelheim GmbH, Charlesson LLC., Circadian Technologies Limited, Clearside BioMedical, Inc., EyeCyte, Inc., F. Hoffmann-La Roche Ltd., Genzyme Corporation, GlaxoSmithKline plc, iCo Therapeutics Inc., Icon Bioscience, Inc., Iconic Therapeutics, Inc., Intas Pharmaceuticals Ltd., Kala Pharmaceuticals, Inc., Lpath, Inc., Mesoblast Limited, Neurotech Pharmaceuticals, Inc., Novartis AG, Ohr Pharmaceutical Inc., Ophthotech Corp., Oxford BioMedica plc, PanOptica, Inc., Pfenex Inc., Pfizer Inc., pSivida Corp., Quark Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc., ReGenX Biosciences, LLC, Resolvyx Pharmaceuticals, Inc, Santen Pharmaceutical Co., Ltd., Sanwa Kagaku Kenkyusho Co., Ltd., Tacere Therapeutics, Inc., ThromboGenics NV, TRACON Pharmaceuticals, Inc., TWi Pharmaceuticals, Inc.
Posterior Uveitis - Pipeline Review, H2 2014
This report provides comprehensive information on the therapeutic development for Posterior Uveitis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. Companies discuss in the report include ForSight VISION4, Inc., Neuroptis Biotech, pSivida Corp., Regeneron Pharmaceuticals, Inc., Virogenomics, Inc., XOMA Corporation.
About Us:
RnRMarketResearch.com is a database of selected syndicated market research reports for global and regional industries including but not limited to life sciences, information technology & telecommunications, consumer goods, food and beverages, energy and power, automotive and transportation, manufacturing and construction, materials and chemicals, public sector as well as business and financial services. We provide 24/7 online and offline support to our customers.
Contact:
Ritesh Tiwari
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Tel: [phone]
[e-mail]


LOOKS LIKE iCo Therapeutics IS IN PRETTY GOOD COMPANY IN THIS REPORT.


ICOTF IS THE REAL DEAL! WATCH FOR SOME GREAT DEVELOPMENTS TO BE ANNOUNCED IN THE VERY NEAR FUTURE!




.